Skip to content

Prof. Stephen Chan

269
Prof. Stephen Chan
陳林教授
Share
qualifications
MBBS (HK), MD (CUHK), MRCP (UK), FHKCP, FHKAM (Medicine), FRCP (Edin), FRCP (Lond)
rank
Ip's Family Trust Professor of Clinical Oncology
Assistant Dean (Health Systems), Faculty of Medicine
orcid
0000-0001-8998-5480
email
chanlam_stephen@cuhk.edu.hk

Specific Research / Sites of Interest

Clinical and translational researches on hepato-pancreatobiliary cancers and neuroendocrine tumours

Short Biography

Professor Chan is currently the clinical professor at the Department of Clinical Oncology of The Chinese University of Hong Kong.

Prof. Chan graduated from the University of Hong Kong and received the gold medal dissertation award and young investigator award by the Hong Kong College of Physicians.

Over the past 20 years, Prof. Chan has dedicated his time on advancing the clinical management of hepatobiliary, pancreatic and neuroendocrine tumours via clinical trials and scientific researches. He published over 200 papers in peer reviewed journals.

Prof. Chan is active both locally and internationally with leadership positions including


  • Associate Editor, Journal of Hepatology (IF 25.7 in 2022)

  • Head of External Relations, Executive Committee, the International Liver Cancer Association (ILCA)

  • Panel Member, Biology and Medicine Panel for the General Research Fund, Hong Kong

  • Founding Chair, the Hand-in-Hand cancer foundation, Hong Kong


Most Representative Publications

1. Wong GL, Wong VW, Hui VW, Yip TC, Tse YK, Liang LY, Lui RN, Mok TS, Chan HL, Chan SL*. Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus Infection (*corresponding authors). Am J Gastroenterol. 2021; 116: 1274-1283.
2. Yoo C, Kim JH, Ryu MH, Park SR, Lee D, Kim KM, Shim JH, Lim YS, Lee HC, Lee J, Tai D, Chan SL*, Ryoo BY. Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study (*Corresponding author). Liver Cancer 2021; 10: 107-114.
3. Bruix J, Chan SL, Galle PR, Rimassa L, Sangro B. Systemic treatment of hepatocellular carcinoma. An EASL position paper. J Hepal. 2021; S0168-8279.
4. Chan SL, Galle PR, Rimassa L, Sangro B. Systemic treatment of hepatocellular carcinoma. An EASL position paper. J Hepal. 2021; S0168-8279.
5. Chan SL, Wong, LL, Chan KCA, Chow C, Tong JHM, Yip TCF, Wong GLH, Chong CCN, Liu PH, Chu CM, Wong VW, To KF, Reeve HL, Chan AWH. Development of a novel inflammation-based index for hepatocellular carcinoma. Liver Cancer. 2020; 9: 167-181.
6. Sangro B, Chan SL, Meyer T, Reig M, El-Khoueiry A, Galle PR. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. J Hepatol. 2020; 72: 320-341.
7. Cheng AL, Hsu C., Chan SL, Choo SP, Kudo M. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol. 2020; 72: 307-319.
8. Abou-alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin R, Merle P, Chen YH, Park JW, Blanc JF, Bolondi L, Klumpen HJ, Chan SL, Zagonel V, Pressiani T, Ryu MH, Venook AP, Hessel C, Borgman-Hagey A, Schwab G, Kelley RK. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018; 379: 54-63
9. Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Webber AL, Ebbinghaus SW, Ma J, Siegel AB, Cheng AL, Kudo M. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018; 19: 940-952.
10. Chan SL, Yeo W, Mo F, Chan AW, Koh J, Li L, Hui EP, Chong CN, Lai PB., Mok TS., Yu, SC. A phase II study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma. Cancer. 2017; 123: 3977-3985.
11. Chan SL, Chan AW, Chan AK, Jian P, Mo F, Chan CM, Mok K, Liu C, Chong CC, Chan AT, Mok T, Yeo W. Systemic evaluation of circulating inflammatory markers for hepatocellular carcinoma. Liver Int 2017; 37:280-289.
12. Chan SL, Wong VW, Qin S, Chan HL. Infection and Cancer: the case of hepatitis B. J Clin Oncol. 2016; 34: 83-90
13. Wong VW*, Chan SL*, Mo F, Chan TC, Loong HH, Wong GL, Lui YY, AT Chan, Sung JJ, Yeo W, Chan HL, Mok TS. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. (*equal contribution). J Clin Oncol 2010; 28: 1660-1665.
14. Chan SL, Mo F, Johnson PJ, Hui EP, Ma BB, Ho WM, Lam KC, Chan AT, Mok TS, Yeo W. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiological response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 2009; 27: 446-452